Alitheia Holdings

Alitheia Holdings is a San Diego-based biotechnology company focused on developing innovative diagnostics and therapeutics, primarily based on research from the University of California, San Diego (UCSD). The company operates through two main technology pillars: the EV-CATCHER platform for high-throughput isolation and molecular profiling of extracellular vesicles (EVs), and a pipeline of telomerase-based cancer vaccines. The EV-CATCHER technology enables non-invasive liquid biopsies for early cancer detection and treatment monitoring, while the vaccine program targets telomerase reverse transcriptase (TERT) to stimulate immune responses against a broad range of solid tumors. Alitheia Holdings aims to integrate these technologies to provide a comprehensive approach to precision oncology. The company leverages the expertise of its founders in nanotechnology, oncology, and immunology to advance its programs toward clinical validation.